These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23588841)

  • 21. New tests for prostate cancer.
    O'Hanlon LH
    J Natl Cancer Inst; 2013 Nov; 105(22):1672-4. PubMed ID: 24198330
    [No Abstract]   [Full Text] [Related]  

  • 22. Screening for prostate cancer - will we ever know?
    Adolfsson J
    Acta Oncol; 2010 Apr; 49(3):275-7. PubMed ID: 20397764
    [No Abstract]   [Full Text] [Related]  

  • 23. Re: Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?
    Ansari MS
    J Urol; 2002 Jul; 168(1):200; author reply 200-1. PubMed ID: 12050532
    [No Abstract]   [Full Text] [Related]  

  • 24. Is an improved PSA screening test in sight?
    Savage L
    J Natl Cancer Inst; 2007 Oct; 99(20):1503-4. PubMed ID: 17925529
    [No Abstract]   [Full Text] [Related]  

  • 25. What's wrong with chemoprevention of prostate cancer?
    Justman S
    Am J Bioeth; 2011 Dec; 11(12):21-5. PubMed ID: 22146025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening for prostate cancer: prostate-specific antigen testing is not effective.
    Hitzeman N; Molina M
    Am Fam Physician; 2011 Apr; 83(7):802-4. PubMed ID: 21524045
    [No Abstract]   [Full Text] [Related]  

  • 27. Early detection of prostate cancer.
    Loeb S; Cooperberg MR
    Urol Clin North Am; 2014 May; 41(2):xiii. PubMed ID: 24725496
    [No Abstract]   [Full Text] [Related]  

  • 28. [The use of prostate specific antigen in prostate cancer--prediction for treatment failure].
    Egawa S
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():100-6. PubMed ID: 12599553
    [No Abstract]   [Full Text] [Related]  

  • 29. New PSA guidelines discourage overscreening.
    Peres J
    J Natl Cancer Inst; 2012 Jan; 104(1):8-9. PubMed ID: 22173585
    [No Abstract]   [Full Text] [Related]  

  • 30. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
    Welch HG; Fisher ES; Gottlieb DJ; Barry MJ
    J Natl Cancer Inst; 2007 Sep; 99(18):1395-400. PubMed ID: 17848671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Legal (liability) aspects of PSA determination].
    Mielke K
    Urologe A; 2006 Jun; 45(6):756-65. PubMed ID: 16788794
    [No Abstract]   [Full Text] [Related]  

  • 32. PSA-based screening for prostate cancer. Too many adverse effects.
    Prescrire Int; 2012 Sep; 21(130):215-7. PubMed ID: 23016259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early detection of prostate cancer.
    Taneja SS
    Urol Clin North Am; 2014 May; 41(2):xi-xii. PubMed ID: 24725495
    [No Abstract]   [Full Text] [Related]  

  • 34. [Urologists introduce a new round of prostate specific antigen discussion].
    Aktuelle Urol; 2013 Jul; 44(4):257-8. PubMed ID: 23904120
    [No Abstract]   [Full Text] [Related]  

  • 35. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Rosser CJ; Parker A
    J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
    [No Abstract]   [Full Text] [Related]  

  • 36. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
    Krahn MD; Coombs A; Levy IG
    CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
    Thompson IM; Tangen CM; Kristal AR
    J Natl Cancer Inst; 2008 Nov; 100(21):1487-8. PubMed ID: 18957671
    [No Abstract]   [Full Text] [Related]  

  • 38. Measuring the importance of PSA velocity.
    Tuma RS
    J Natl Cancer Inst; 2011 Mar; 103(6):454-61. PubMed ID: 21393606
    [No Abstract]   [Full Text] [Related]  

  • 39. Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
    Hamilton RJ; Platz EA; Freedland SJ
    J Natl Cancer Inst; 2009 Apr; 101(8):611-2. PubMed ID: 19351913
    [No Abstract]   [Full Text] [Related]  

  • 40. Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators.
    Nam RK; Kattan MW; Chin JL; Trachtenberg J; Singal R; Rendon R; Klotz LH; Sugar L; Sherman C; Izawa J; Bell D; Stanimirovic A; Venkateswaran V; Diamandis EP; Yu C; Loblaw DA; Narod SA
    J Clin Oncol; 2011 Aug; 29(22):2959-64. PubMed ID: 21690464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.